• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Transdermal CNS Therapeutics: Products, Pipeline Candidates, Markets, Forecasts - Product Image

Transdermal CNS Therapeutics: Products, Pipeline Candidates, Markets, Forecasts

  • Published: June 2011
  • Region: Global
  • Greystone Associates

Current disease trends point to increasing morbidity and mortality associated with CNS ailments in the general population. These trends include the growing incidence of neurological disorders associated with longevity and aging, and significant increases in the number of children diagnosed with autism. Because diseases of the central nervous system often result in compromised cognitive and/or motor skills that can increase the level of involuntary non-compliance with therapeutic protocols, transdermal delivery of drugs targeting CNS disorders is generally viewed as a method that can increase patient safety and improve outcomes. In addition to the handful of FDA-approved transdermal CNS products, more than a dozen companies are currently pursuing a range of APIs in transdermal delivery systems that target neurological and CNS conditions. While none of these development-stage candidates is curative, the benefits they can offer in terms of patient ease-of-use, product safety and overall quality-of-care are expected to result in reduced morbidity and more effective symptom management for afflicted patients.

- Analyzes and evaluates the global market opportunity for READ MORE >

Executive Summary
- The Current CNS Drug Therapeutics Market
- Unmet Needs in CNS Disease Treatment
- The Opportunity for Transdermal Delivery of CNS Therapeutics

The CNS Therapeutics Market Opportunity
- Changes and Trends in Incidence and Morbidity
- The Demand Picture for CNS Therapeutics
- Competitive Landscape
- Factors Limiting Growth

Transdermal Drug Delivery to the CNS
- Patch Designs and Construction
- Transdermal Patch Manufacturing and Packaging
- The Patch Manufacturing Ecosystem
- CNS Patch Economics
- Passive vs Active Delivery Systems

The Global Market for Transdermal CNS Therapeutics –Disease Segment Analysis
- Alzheimer's Disease
- Dementia
- Depression
- Migraine
- Nausea
- Parkinson's Disease
- Restless Leg Syndrome
- Schizophrenia

Transdermal CNS Drug Product Analysis and Market Assessments
- FDA Approved Transdermal CNS Prescription Products
- MAO Inhibitors
- Cholinergic Agents
- Dopamine Agonists
- CNS Stimulants
- 5-HT3 Receptor Antagonists
- Non-FDA Approved Commercial Transdermal CNS Products
- Non-U.S. Regional Product Assessment & Market Impact
- Strategic Factors and Branding Issues
- Development-Stage Transdermal CNS Prescription Products
- AChE Inhibitors
- Cholinergic Agents
- Dopamine Agonists
- 5-HT3 Receptor Antagonists
- Serotonin Agonists
- Other Drug Classes

Transdermal CNS Therapeutics Market Data & Forecasts

Market Factors
- Regulations and Approvals
- Clinical Trials
- Indications Prescribing Guidelines and Off-Label Prescribing
- Rx-to-OTC Switching
- Skin Patch Revenue Models

Market Participant Profiles

Note: Product cover images may vary from those shown


Our Clients

Our clients' logos